reports
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscula...
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference - Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD - - Oral presentation on Phase 3 trial design for z-basivarsen in DM1 - - Five total presentations across three neuromuscular diseases demonstrate strength of Dyne’s pipeline based on clinically-validated FORCE™ platform - WALTHAM, Mass., Feb. 22, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DYN), a clinical-stage company focused on delivering fun...
- ABGSC Seafood Research
- Martin Kaland
- Oliver Dunvold
Canacol Energy Announces Leadership Change and Independent Director Ap...
Canacol Energy Announces Leadership Change and Independent Director Appointment CALGARY, Alberta, Feb. 22, 2026 (GLOBE NEWSWIRE) -- (“Canacol” or the “Company”) announces a leadership change and the appointment of an independent director to the board of directors (the “Board”). The Board believes that these changes will position the Company for success in the next phase of its restructuring by adding substantial restructuring experience to the Board. Mr. Jason Bednar, Canacol’s Chief Financial Officer, and Mr. Ravi Sharma, Canacol’s Chief Operating Officer, will assume roles as Interim C...
nVent Postpones Investor Day due to Weather-related State of Emergency...
nVent Postpones Investor Day due to Weather-related State of Emergency Declared in New York City Metropolitan Area LONDON, Feb. 22, 2026 (GLOBE NEWSWIRE) -- nVent Electric plc (NYSE: NVT) (“nVent”), a global leader in electrical connection and protection solutions, today announced that it is postponing its Investor Day, originally scheduled for February 24, 2026, due to a state of emergency declared for the New York metropolitan area ahead of a major winter storm, expected to bring blizzard conditions. nVent is currently evaluating scheduling options. A formal invitation will be issued o...
MoonLake Announces Positive Topline Results from its Phase 2 Clinical ...
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12Consistently, other clinical and imaging scores also showed improvements of 80+% by week 12 for patients treated with SLK, including ASDAS-CRP and SPARCC MRIaxSpA is a disease driven by inflammation leading to irreversible ossification (via osteoblast activit...
- Carsten Brzeski
- James Knightley
Dassault Systèmes’ CEO Pascal Daloz becomes also Chairman of the Board...
Dassault Systèmes’ CEO Pascal Daloz becomes also Chairman of the Board of Directors of Dassault Systèmes Press ReleaseVELIZY-VILLACOUBLAY, France — February 21, 2026 Dassault Systèmes’ CEO Pascal Daloz becomes also Chairman of the Board of Directors of Dassault Systèmes Bernard Charlès announces stepping down from his Executive Chairman and Member of the Board positions, for personal reasonsBernard Charlès intends to put his 43 years of industry experience, and his vision to transform, with AI, industrial creation and production processes, at the service of the Generative Economy Pascal D...
Dassault Systèmes annonce la nomination de Pascal Daloz comme Préside...
Dassault Systèmes annonce la nomination de Pascal Daloz comme Président-Directeur Général de Dassault Systèmes Communiqué de PresseVELIZY-VILLACOUBLAY – 21 Février 2026 Dassault Systèmes annonce la nomination de Pascal Daloz comme Président-Directeur Général de Dassault Systèmes Bernard Charlès annonce se retirer de ses fonctions de Président du Conseil et d’administrateur, pour raisons personnelles Bernard Charlès entend mettre ses 43 années d’expérience dans l’industrie, ainsi que sa vision de la transformation par l’IA des processus industriels de création et de production, au servic...
SKAGI: Samrunaviðræðum Skaga hf. og Íslandsbanka hf. slitið
SKAGI: Samrunaviðræðum Skaga hf. og Íslandsbanka hf. slitið Með vísan til tilkynningar frá 6. október 2025, þar sem greint var frá undirritun samkomulags um helstu skilmála samruna („samkomulagið“) á milli Íslandsbanka hf. („Íslandsbanki“) og Skaga hf. („Skagi“), tilkynnir stjórn Skaga hér með um að samrunaviðræðum félaganna hefur verið slitið. Stjórn Skaga harmar að þetta sé niðurstaða þess ferlis sem lagt var upp með enda er það mat hennar að verulegur ávinningur yrði af samruna félaganna og tækifæri til framtíðar fyrir alla hagaðila. Samruni við Íslandsbanka var í samræmi við stefnu fé...
Ændring i ledelsen
Ændring i ledelsen Selskabsmeddelelse nr. 08/2026København, den 21. februar 2026 I forbindelse med optimering af selskabets eksterne udviklingsteam har Unlimit Group besluttet at afslutte samarbejdet med CTO Haris Aftab, da hans primære funktion som projektleder af dette team ikke har fungeret som ønsket. Fremadrettet ledes udviklingsteamet af CEO Jan Bo Sørensen. Ændringen påvirker ikke selskabets forventninger til omsætning eller indtjening for indeværende regnskabsår. *** Unlimit Group A/S | Cvr. nr. 34472742 | unlimitgroup.dk/Investor/ Certified AdviserKapital Partner A/S (CVR-nr....
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimo...
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel diseaseAnti-fibrotic effects of obefazimod were observed in both a ...
Resouro Strategic Metals Inc: 1 director
Two Directors at Resouro Strategic Metals Inc sold/bought 135,000 shares at between 0.375CAD and 0.390CAD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's ...
Sprott Inc: 1 director
A director at Sprott Inc sold 6,300 shares at 141.473USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Iamgold Corp: 1 director
A director at Iamgold Corp sold 13,727 shares at 30.720CAD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Maple Gold Mines Ltd: 1 director
A director at Maple Gold Mines Ltd subscribed to 15,000 shares at 2.450CAD and the significance rating of the trade was 47/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Enad Global 7 AB: 2 directors
A director at Enad Global 7 AB bought 661,848 shares at 13.893SEK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Vistin Pharma ASA: 1 director
A director at Vistin Pharma ASA bought 30,000 shares at 21.100NOK and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Preatoni Group S.A: 1 director
A director at Preatoni Group S.A sold 207,313 shares at 0.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.